Push-pull model of wound healing
described.
by Lesney, Mark S.
WASHINGTON -- The vascular surgeon insists that revascularization
was a success--and there are outcome images to prove it but the diabetic
foot becomes ischemic anyway, and the wound fails to heal.
This is an all too common scenario for physicians who care for
these at-risk limbs and problem wounds. Such failures can be explained
in a push-pull model of perfusion in these patients, and this model may
well indicate what needs to be done for effective treatment, according
to Dr. William J. Ennis.
The push-pull model essentially states that despite the
"push" of restored macro-circulation from revascularization,
the patient still needs the ability to "pull" blood nutrients
into all parts of the limb via a functional microcirculation, said Dr.
Ennis of the St. James Center for Comprehensive Wound & Disease
Management in Chicago. He spoke at a meeting sponsored by George
Washington University Hospital.
But creating "pull" is not an easy task, especially for
patients with diabetes. In such individuals, a functional
microcirculation may be a problem in its own right because of both
physical and physiologic changes in their microvascular system brought
on by the long-term chronic disease. In patients with poor
microcirculation, successful revascularization of the larger vessels can
lead to ischemic reperfusion injury in the tissues that they service.
White cells stick and create reactive oxygen species that make it almost
impossible for wounds to heal.
Damage models in diabetic foot wound responses after
revascularization can borrow from cardiology, according to Dr.
Ennis--concepts such as tissue "stunning," whereby tissue is
traumatized by the reperfusion injury without being killed and remains
capable of recuperating; no reflow, such as that caused by a mechanical
obstruction from thrombus; or functional alterations, such as the
endothelial dysfunction that is known to occur in diabetics.
It is critical to restore a microvascular "pull" as soon
as possible in order for the wound to heal and, in many cases, in order
for the limb to survive, according to Dr. Ennis. "It is almost
silly for us to think that we can solve the entire process with a simple
bypass. We may end up with a mixed pattern, persistent ischemia, and
something known as no reflow. These are the patients who get bypass and
nothing happens--the wound continues or the open-air site never heals
.... It is so frustrating for us as wound clinicians to see a great
bypass and still lose a limb. It's not uncommon, and this
[microcirculatory problem] is why."
Angiogenesis agents are one option for restoring microcirculatory
"pull." One such treatment may be ultrasound. Pulsatile flow
in tissue pushes and pulls on the endothelium and causes nitric oxide
release. Ultrasound can be used to "fake the tissue out that it is
receiving pulsatile flow," according to Dr. Ennis, who along with
his colleagues has studied the use of ultrasound to induce angiogenesis,
pulsatile flow, and ultimately wound healing.
"We were able to show that there was a difference in
angiogenesis at approximately 4 1/2 weeks with ultrasound therapy. ...
This was one of the first times we were actually able to quantify the
angiogenesis response and correlate it to wound healing," he
explained (Advances in Skin & Wound Care 2006; 19:437-46).
The future may include novel treatments for reperfusion injury and
ischemia such as bone marrow stem cell therapy, which may be available
in 5-10 years, and growth factor molecules, many of which are currently
being tested in phase I trials, according to Dr. Ennis.
Regardless of which treatment is chosen, it is also important for
the vascular and wound-care teams to collaborate on prevention of
ischemia after revascularization, Dr. Ennis stated. The certainty of
appropriate return of macrovascular circulation must be confirmed, and
all other barriers to blood flow need to be addressed.
Preoperatively, it may be possible to use free-radical scavengers
or systemic vasodilators. Postoperatively, he advised that tissue-level
perfusion be tested for adequacy of revascularization and cautioned
against relying on the return of palpable pulse or flow in the bypass
graft to do that.
Dr. Ennis disclosed that he was a consultant and received an
honorarium from Celleration, which manufactures an ultrasound device for
stimulation of wound healing.
BY MARK S. LESNEY
Senior Editor
COPYRIGHT 2008 International Medical News
Group Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2008 Gale, Cengage Learning. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.